Mycofenolaatmofetil Auro (Mycophenolate Mofetil)

Mycophenolate mofetil is converted to mycophenolic acid, which blocks the enzyme inosine monophosphate dehydrogenase. This inhibition stops the synthesis of guanine nucleotides, a critical step for the proliferation of T‑ and B‑lymphocytes, thereby reducing immune‑mediated damage.

The dosage of Mycofenolaatmofetil Auro is individualized. A qualified prescriber determines the appropriate amount based on the patient’s clinical condition, transplant type, renal function and other factors. Patients should follow the prescribing information provided by their healthcare professional.

Mycophenolate mofetil is classified as Pregnancy Category X because it can cause fetal malformations and pregnancy loss. It is contraindicated in pregnant women and should be stopped before conception. Breastfeeding is also not recommended, as the drug is excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism by targeting lymphocyte proliferation rather than cytokine production. It is often used in combination regimens to provide synergistic immunosuppression while allowing lower doses of each agent, potentially reducing toxicity.

Store Mycofenolaatmofetil Auro at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, heat and direct sunlight, and ensure the packaging remains tightly closed until use.

The medication is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. Patients should swallow the dosage form whole and avoid crushing or chewing unless specifically instructed.

Serious risks include severe infections, opportunistic infections such as PML, significant bone‑marrow suppression leading to leukopenia or anaemia, and teratogenic effects causing fetal harm. Prompt medical attention is required if any signs of infection, unusual bleeding, or pregnancy occur.

Mycofenolaatmofetil Auro is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate mofetil or any excipients, and patients with uncontrolled severe infections. Caution is also advised for those with significant renal impairment or a history of malignancy.